Overlooked Covid-19 Vaccine Runners Up Defended by Wall Street
Three potential coronavirus vaccines sit in a tray at Novavax labs in Rockville, Maryland on March 20.
Photographer: Andrew Caballero-Reynolds/AFP via Getty Images
This article is for subscribers only.
Don’t give up hope for Novavax Inc. and Inovio Pharmaceuticals Inc., Wall Street analysts said after the two failed to appear on a Trump administration list of Covid-19 vaccine developers picked for Operation Warp Speed.
The pair slid more than 10% on Wednesday following a New York Times report saying that the White House’s list included larger drugmakers such as AstraZeneca PLC, Johnson & Johnson, Merck & Co. and Pfizer Inc., but not the pair of small-caps.